Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD



Status:Terminated
Conditions:Chronic Obstructive Pulmonary Disease
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:40 - 80
Updated:4/6/2019
Start Date:December 9, 2016
End Date:June 20, 2018

Use our guide to learn which trials are right for you!

A Randomized, Phase IIIb, Two-period , Double-blind, Two-treatment, Chronic-dosing (7 Days), Single-center Crossover Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease, Compared With Placebo

This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7
days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003
compared with that of Placebo MDI on Cardiovascular Hemodynamics following chronic-dosing (7
days) in subjects with moderate to severe COPD.


Inclusion Criteria:

- At least 40 years of age and no older than 80 at Visit 1.

- Women of non-child bearing potential,or negative serum pregnancy test at Screening,
and agrees to acceptable contraceptive methods used consistently and correctly from
Screening until 14 days after final visit

- Evidence of lung hyperinflation

- Subjects with an established clinical history of COPD as defined by the American
Thoracic Society (ATS)/European Respiratory Society (ERS)

- Current or former smokers with a history of at least 10 pack-years of cigarette
smoking.

- Pre- and Post-bronchodilator FEV1/FVC ratio must be <0.70

- Post-bronchodilator FEV1 must be ≥30% to <65% predicted normal value, calculated using
NHANES III reference equations.

Exclusion Criteria:

- Significant diseases or conditions other than COPD which, in the opinion of the
Investigator, may put the patient at risk

- Women who are pregnant or lactating or are planning to become pregnant during the
course of the study

- Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma
or other active pulmonary disease

- Subjects who have been hospitalized due to poorly controlled COPD within 3 months
prior to Screening

- Subjects who have poorly controlled COPD, defined as acute worsening of COPD that
requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to
Screening or during the Screening Period

- Subjects who have clinically significant uncontrolled hypertension.

- Subjects with symptomatic prostatic hypertrophy that is clinically significant and not
adequately controlled with appropriate therapy, in the opinion of the Investigator.

- Subjects with bladder neck obstruction or urinary retention that is clinically
significant in the opinion of the Investigator.

- Subjects with a calculated creatinine clearance ≤30 mL/minute using Chronic Kidney
Disease Epidemiology Collaboration. (CKD-EPI) formula at Screening and on repeat
testing prior to Visit 2.

- Subjects with abnormal liver function tests defined as AST, ALT, or total bilirubin ≥
1.5 times upper limit of normal at Screening and on repeat testing prior to Visit 2

- Subjects who have cancer that has not been in complete remission for at least five
years.

- Subjects with a diagnosis of glaucoma, who in the opinion of the Investigator, have
not been adequately treated.

- Subjects with a clinically significant ECG

- Subjects who were previously enrolled in any previous PT001, PT003, or PT005 study
conducted or sponsored by Pearl.
We found this trial at
3
sites
Philadelphia, Pennsylvania
?
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Birmingham, Alabama
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Denver, Colorado
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials